616MO Efficacy of BN-brachyury (BNVax) + bintrafusp alfa (BA) + N-803 in castration-resistant prostate cancer (CRPC): Results from a preliminary analysis of the Quick Efficacy Seeking Trial (QuEST1)
Jason M. Redman(National Institutes of Health), James L. Gulley(National Cancer Institute), Jennifer L. Marté(National Cancer Institute), Julius Strauss(National Cancer Institute), M.A. Mañú(Indian Agricultural Research Institute), Lisa M. Cordes(National Institutes of Health Clinical Center), Amy Hankin(National Institutes of Health), Seth M. Steinberg(National Institutes of Health), Margaret E. Gatti‐Mays(National Cancer Institute), Marijo Bilušić(National Institutes of Health), Charalampos S. Floudas(National Cancer Institute), Jeffrey Schlom(National Cancer Institute), Fatima Karzai(National Institutes of Health), Houssein Abdul-Sater(National Institutes of Health), N. Williams(National Institute of Allergy and Infectious Diseases), Ravi A. Madan(National Cancer Institute), William L. Dahut(National Cancer Institute)
Cited by 6
Related Papers
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy
|The Journal of Experimental Medicine|2006|1.7k
Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
|Journal of Clinical Oncology|2010|975
Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide
|Blood|2005|896
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817